Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 211-218 , February 2010

Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis

  • Chunyu Zhang

      Affiliations

    • Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital; Fudan University, 180 Fenglin Road, Shanghai 200032, China
    • These authors contributed equally to this work.
    • ,
  • Aijun Sun

      Affiliations

    • Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital; Fudan University, 180 Fenglin Road, Shanghai 200032, China
    • These authors contributed equally to this work.
    • ,
  • Peng Zhang

      Affiliations

    • Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital; Fudan University, 180 Fenglin Road, Shanghai 200032, China
    • ,
  • Chaoneng Wu

      Affiliations

    • Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital; Fudan University, 180 Fenglin Road, Shanghai 200032, China
    • ,
  • Shuning Zhang

      Affiliations

    • Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital; Fudan University, 180 Fenglin Road, Shanghai 200032, China
    • ,
  • Mingqiang Fu

      Affiliations

    • Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital; Fudan University, 180 Fenglin Road, Shanghai 200032, China
    • ,
  • Keqiang Wang

      Affiliations

    • Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital; Fudan University, 180 Fenglin Road, Shanghai 200032, China
    • ,
  • Yunzeng Zou

      Affiliations

    • Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital; Fudan University, 180 Fenglin Road, Shanghai 200032, China
    • Institute of Biomedical Science, Fudan University, 138 Yixueyuan Road, Shanghai 200032, China
    • ,
  • Junbo Ge

      Affiliations

    • Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital; Fudan University, 180 Fenglin Road, Shanghai 200032, China
    • Institute of Biomedical Science, Fudan University, 138 Yixueyuan Road, Shanghai 200032, China
    • Corresponding Author InformationCorresponding author at: Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital; Fudan University, 180 Fenglin Road Shanghai 200032, China. Tel.: +86 21 6404 1990x2745; fax: +86 21 6443 7078.

Received 3 September 2009 ,Accepted 28 September 2009.

References 

  1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes – Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053
  2. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus – A scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114–126
  3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998;339:229–234
  4. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. Med. 2005;352:1293–1304
  5. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes a randomized controlled trial. JAMA. 2008;300:2134–2141
  6. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet. 1999;354:1896–1900
  7. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002;21:1539–1558
  8. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  9. Hennekens CH. Final report on the aspirin component of the ongoing physicians health study. N. Engl. J. Med. 1989;321:129–135
  10. Ferris FL, Kassoff A, Buzney SM, McMeel JW, Weiter JJ, Doyle GJ, et al. Aspirin effects on mortality and morbidity in patients with diabetes mellitus - early treatment diabetic-retinopathy study report-14. JAMA. 1992;268:1292–1300
  11. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet. 1998;351:1755–1762
  12. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the primary prevention project (PPP) trial. Diabetes Care. 2003;26:3264–3272
  13. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337
  14. Zanchetti A. Aspirin and antiplatelet drugs in the prevention of cardiovascular complications of diabetes. In:  Mogensen CE editors. Pharmacotherapy of Diabetes: New Developments: Improving Life and Prognosis for Diabetic Patients. USA: Springer; 2007;p. 211–218
  15. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am. J. Med. 2008;121:43–49
  16. Collins R, Peto R, Hennekens C, Doll R, Bubes V, Buring J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860
  17. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183–1187
  18. Watala C, Rozalski M, Kropiwnicka A, Golanski J, Wieclawska B, Drzewoski J. Resistance or reduced sensitivity to aspirin occurs more frequently in diabetic patients and is related to nonenzymatic protein glycosylation. Diabetes Res. Clin. Pract. 2000;50:S135
  19. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia. 2008;51:385–390
  20. Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs. 2007;67:997–1026
  21. Evangelista V, Totani L, Rotondo S, Lorenzet R, Tognoni G, De Berardis G, et al. Prevention of cardiovascular disease in type-2 diabetes: How to improve the clinical efficacy of aspirin. Thromb. Haemost. 2005;93:8–16
  22. Fateh-Moghadam S, Plockinger U, Cabeza N, Htun P, Reuter T, Ersel S, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol. 2005;42:99–103
  23. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men – A sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306–313
  24. Zuern CS, Lindemann S, Gawaz M. Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management. Semin. Thromb. Hemost. 2009;35:295–306
  25. Johnson M, Ramey E, Ramwell PW. Sex and age-differences in human platelet-aggregation. Nature. 1975;253:355–357
  26. Faraday N, GoldschmidtClermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb. Haemost. 1997;77:748–754
  27. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 2006;295:1420–1427
  28. Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772
  29. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125
  30. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
  31. Gerstein HC, Yusuf S, Mann JFE, Hoogwerf B, Zinman B, Held C, et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–259
  32. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003;348:383–393
  33. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 2008;358:580–591
  34. De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT- D): Design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007;8:21
  35. A Study of Cardiovascular Events in Diabetes. <http://www.ctsu.ox.ac.uk/ascend/about_pro.htm/>, (accessed 01.08.09).

PII: S0168-8227(09)00421-5

doi: 10.1016/j.diabres.2009.09.029

Diabetes Research and Clinical Practice
Volume 87, Issue 2 , Pages 211-218 , February 2010

Article Tools

* Image Usage & Resolution